Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Pharmacokinetics of Retapamulin in Pediatric Subjects With Uncomplicated Skin Infections.

This study has been completed.
Information provided by (Responsible Party):
GlaxoSmithKline Identifier:
First received: November 6, 2007
Last updated: November 1, 2012
Last verified: October 2012
A study to evaluate the pharmacokinetics of Retapamulin Ointment, 1%, in pediatric subjects (2-24 months) with secondarily-infected traumatic lesions, secondarily-infected dermatoses, or impetigo (bullous and non-bullous).

Condition Intervention Phase
Skin Infections, Bacterial
Drug: Retapamulin Ointment, 1%
Phase 4

Study Type: Interventional
Study Design: Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-Label, Non-Comparative Study to Assess the Pharmacokinetics, Safety and Efficacy of Topical Retapamulin (SB-275833) Ointment, 1%, Twice Daily for Five Days in the Treatment of Uncomplicated Skin and Skin Structure Infections in Pediatric Subjects Aged 2 to 24 Months

Resource links provided by NLM:

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Number of Participants With Measurable Plasma Concentrations, by Age Group [ Time Frame: Days 3 to 4; 4 to 8 hours post-dose of the first dose of the day ] [ Designated as safety issue: No ]
    Pharmacokinetic (PK) samples were collected randomly in the window of 4 to 8 hours post-dose (except one at 3 hours and one at 11 hours post-dose) after the first daily dose of treatment on Day 3 or Day 4. The lower limit of quantification (LLQ) for retapamulin was 0.5 ng/mL.

Secondary Outcome Measures:
  • Number of Participants With Clinical Success at Follow-up, by Type of Skin Infection and by Age [ Time Frame: Follow-up, Days 12 to 16 ] [ Designated as safety issue: No ]
    SID = Secondarily Infected Dermatoses; SITL = Secondarily Infected Traumatic Lesions. Clinical Success is the number of participants with resolution of signs/symptoms of infection or improvement such that no additional antibiotic therapy was needed.

  • Bacteriological Success Rate at Follow-up, by Baseline Pathogen [ Time Frame: Follow-up, Days 12 to 16 ] [ Designated as safety issue: No ]
    Bacteriological success is defined as: (1) Bacteriological Eradication, elimination of the baseline pathogen via culture results; (2) Presumed Bacteriological Eradication, clinical success plus no culturable material from the wound; or (3) Colonization, new pathogen identified at Follow-up in a non-symptomatic participant who does not require additional antibiotic therapy. The number of pathogens eradicated out of the number isolated (shown as "n" in the category title) for each respective category is shown.

  • Number of Participants by Age With Therapeutic Response of Success [ Time Frame: Follow-up, Days 12 to 16 ] [ Designated as safety issue: No ]
    Therapeutic response is a measure of the overall efficacy response; a response of "therapeutic success" was based on both clinical success and bacteriological success in a given participant.

Enrollment: 60
Study Start Date: September 2007
Study Completion Date: August 2008
Primary Completion Date: August 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm 1
Single Arm Retapamulin 1% Ointment
Drug: Retapamulin Ointment, 1%
1% Ointment
Other Names:
  • Retapamulin Ointment
  • 1%


Ages Eligible for Study:   2 Months to 24 Months   (Child)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • Subject Age: The subject is ≥2 months to ≤24 months of age at study entry
  • Subject Diagnosis: The subject has a diagnosis of secondarily-infected traumatic lesion (SITL), secondarily-infected dermatoses (SID), or primary impetigo (bullous or non-bullous) that is suitable for treatment with topical antibacterial therapy:

The subject has a small laceration, sutured wound or abrasion, which has a secondary bacterial infection. The infected portion of the laceration or sutured wound should not exceed 10cm in length with surrounding erythema not extending more than 2cm from the edge of the wound. Abrasions should not exceed 2% of the total body surface area with surrounding erythema not extending more than 2cm from the edge of the abrasion.

The subject has a diagnosis of inflammatory skin disease (i.e., dermatosis), such as atopic dermatitis or contact dermatitis, which has a secondary bacterial infection. The infected portion of the lesion(s) should not exceed 2% of the total body surface area.

Impetigo: The subject has a lesion or group of £10 discrete localized lesions on otherwise healthy skin, characterized by red spots or blisters without crusts which later progress to lesions which ooze and form yellow or honey-colored crusts surrounded by an erythematous margin.

  • Subject SIRS Score: The subject has a total SIRS score of at least 8 (Appendix 1 Skin Infection Rating Scale)
  • Protocol Compliance: The parent/legal guardian is willing to comply with the protocol
  • Informed Consent: The parent/legal guardian has given written informed, dated consent for the subject to participate in the study
  • French Subjects: In France, a subject will be eligible for inclusion in this study if either affiliated to or a beneficiary of a social security category

Exclusion criteria:

  • The subject has demonstrated a previous hypersensitivity reaction to pleuromutilin or any component of the ointment (refer to the Investigator Brochure for composition of Retapamulin ointment, 1%)
  • The subject was considered to be premature at birth (<37 weeks gestation)
  • The subject has a secondarily-infected animal/human bite, or a puncture wound
  • The subject has an abscess
  • The subject has a chronic ulcerative lesion that is unlikely to have Staphylococcus aureus or Streptococcus pyogenes as the causative agent
  • The subject has systemic signs and symptoms of infection (such as fever; defined as a temperature equivalent to a rectal temperature greater than 101°F or 38.3°C)
  • The subject has a bacterial skin infection which, due to area, depth or severity, in the opinion of the investigator, cannot be appropriately treated by a topical antibiotic
  • The subject has more than one type of infected lesion as defined in the protocol
  • The subject requires surgical intervention for treatment of the infection prior to enrollment in the study, or is likely to require such intervention during the course of the study
  • The subject has applied any topical therapeutic agent (including glucocorticoid steroids, antibacterials or antifungals) directly to the infected wound/lesion, within 24 hours prior to study entry
  • The subject has received one or more days of treatment with a systemic antibacterial within 72 hours of study entry
  • The subject is receiving systemic corticosteroids at a dose of >0.125mg/kg per day of prednisone (or the equivalent)
  • The subject has a known, pre-existing, serious underlying disease that could be imminently life-threatening
  • The subject has participated in any study using an investigational drug during the previous 30 days prior to entering the study
  • The subject has been previously enrolled in this study or in any other study involving Retapamulin
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00555061

United States, Alabama
GSK Investigational Site
Tuscaloosa, Alabama, United States, 35401
United States, Arkansas
GSK Investigational Site
Bentonville, Arkansas, United States, 72712
United States, California
GSK Investigational Site
Orange, California, United States, 92868
United States, Massachusetts
GSK Investigational Site
Woburn, Massachusetts, United States, 01801
United States, Ohio
GSK Investigational Site
Cleveland, Ohio, United States, 44106
United States, Texas
GSK Investigational Site
Houston, Texas, United States, 77090
GSK Investigational Site
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, C1425BEA
GSK Investigational Site
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
GSK Investigational Site
Santiago, Región Metro De Santiago, Chile, 7580206
Costa Rica
GSK Investigational Site
San Jose, Costa Rica
GSK Investigational Site
Bochum, Nordrhein-Westfalen, Germany, 44791
GSK Investigational Site
Goch, Nordrhein-Westfalen, Germany, 47574
GSK Investigational Site
Alphen A/d Rijn, Netherlands, 2403 JK
GSK Investigational Site
Losser, Netherlands, 7581 BV
GSK Investigational Site
Roelofarendsveen, Netherlands, 2371 RB
GSK Investigational Site
Rotterdam, Netherlands, 3011 TD
GSK Investigational Site
Woerden, Netherlands, 3443 GG
South Africa
GSK Investigational Site
Benoni, South Africa, 1501
GSK Investigational Site
Newtown, South Africa, 2113
Sponsors and Collaborators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

Responsible Party: GlaxoSmithKline Identifier: NCT00555061     History of Changes
Other Study ID Numbers: TOC106489 
Study First Received: November 6, 2007
Results First Received: August 10, 2009
Last Updated: November 1, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by GlaxoSmithKline:
Retapamulin ointment, 1%
Skin abnormalities

Additional relevant MeSH terms:
Communicable Diseases
Bacterial Infections
Skin Diseases, Infectious
Skin Diseases processed this record on December 09, 2016